Cancer in fanconi anemia and fanconi anemia genes in cancer

Monographs in Human Genetics

Volumn 15, Issue , 2007, Pages 59-78

  Neveling, K ^a   Kalb, R ^a   Schindler, D ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35548931929     PISSN: 00770876     EISSN: 16623835     Source Type: Book Series    
DOI: 10.1159/000102548     Document Type: Article

References (87)

1. Park Y, Gerson SL: DNA repair defects in stem cell function and aging. Annu Rev Med 2005;56:495-508. (Pubitemid 40299795)
2. Beckman RA, Loeb LA: Genetic instability in cancer: theory and experiment. Semin Cancer Biol 2005;15:423-435. (Pubitemid 41318043)
3. Thompson LH, Hinz JM, Yamada NA, Jones NJ: How Fanconi anemia proteins promote the four Rs: replication, recombination, repair, and recovery. Environ Mol Mutagen 2005;45:128-142.
4. Alter BP: Cancer in Fanconi anemia, 1927-2001. Cancer 2003;97:425-440. (Pubitemid 36133810)
5. Meyer S, Fergusson WD, Oostra AB, Medhurst AL, Waisfisz Q, et al: A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations. Genes Chromosomes Cancer 2005;42:404-415. (Pubitemid 40271283)
6. Reid S, Renwick A, Seal S, Baskcomb L, Barfoot R, et al: Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J Med Genet 2005;42:147-151. (Pubitemid 40204369)
7. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, et al: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003;101:1249-1256. (Pubitemid 36182492)
8. Alter BP, Caruso JP, Drachtman RA, Uchida T, Velagaleti GV, Elghetany MT: Fanconi anemia: myelodysplasia as a predictor of outcome. Cancer Genet Cytogenet 2000;117:125-131. (Pubitemid 30125811)
9. Auerbach AD, Weiner MA, Warburton D, Yeboa K, Lu L, Broxmeyer HE: Acute myeloid leukemia as the first hematologic manifestation of Fanconi anemia. Am J Hematol 1982;12:289-300. (Pubitemid 12122270)
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199. (Pubitemid 12073508)
11. Fundia A, Gorla N, Larripa I: Spontaneous chromosome aberrations in Fanconi's anemia patients are located at fragile sites and acute myeloid leukemia breakpoints. Hereditas 1994;120:47-50. (Pubitemid 24118576)
12. Ferti A, Panani A, Dervenoulas J, Raptis SA: Cytogenetic findings in a Fanconi anemia patient with AML. Cancer Genet Cytogenet 1996;90:182-183.
13. Oliveira NI, Ribeiro EM, Raimondi SC, Bittencourt MA, Pasquini R, Cavalli IJ: Two different karyotypes with 1q abnormalities in a patient with Fanconi anemia. Leuk Res 2002;26:1047-1049. (Pubitemid 35287217)
14. Tonnies H, Huber S, Kuhl JS, Gerlach A, Ebell W, Neitzel H: Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 2003;101:3872-3874. (Pubitemid 36857860)
15. Alter BP, Joenje H, Oostra AB, Pals G: Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. Arch Otolaryngol Head Neck Surg 2005;131:635-639. (Pubitemid 41058056)
16. Huck K, Hanenberg H, Gudowius S, Fenk R, Kalb R, et al: Delayed diagnosis and complications of Fanconi anaemia at advanced age - a paradigm. Br J Haematol 2006;133:188-197.
17. Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, et al: High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003;129:106-112. (Pubitemid 36070885)
18. Gillison ML, Lowy DR: A causal role for human papillomavirus in head and neck cancer. Lancet 2004;363:1488-1489.
19. Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, et al: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003;95:1718-1721. (Pubitemid 37509080)
20. Van Zeeburg HJ, Snijders PJ, Pals G, Hermsen MA, Rooimans MA, et al: Generation and molecular characterization of head and neck squamous cell lines of Fanconi anemia patients. Cancer Res 2005;65:1271-1276. (Pubitemid 40270153)
21. Hermsen MA, Xie Y, Rooimans MA, Meijer GA, Baak JP, et al: Cytogenetic characteristics of oral squamous cell carcinomas in Fanconi anemia. Fam Cancer 2001;1:39-43.
22. Velazquez I, Alter BP: Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004;77:257-267. (Pubitemid 39430704)
23. Pagano G, Youssoufian H: Fanconi anaemia proteins: major roles in cell protection against oxidative damage. Bioessays 2003;25:589-595. (Pubitemid 36705510)
24. Pagano G, Degan P, D'Ischia M, Kelly FJ, Nobili B, et al: Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. Eur J Haematol 2005;75:93-100. (Pubitemid 41008278)
25. Joenje H, Arwert F, Eriksson AW, De Koning H, Oostra AB: Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. Nature 1981;290:142-143. (Pubitemid 11149688)
26. Schindler D, Hoehn H: Fanconi anemia mutation causes cellular susceptibility to ambient oxygen. Am J Hum Genet 1988;43:429-435.
27. Taniguchi T, D'Andrea AD: The molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006;107:4223-4233. (Pubitemid 43801344)
28. Lyakhovich A, Surralles J: Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett 2006;232:99-106. (Pubitemid 43053937)
29. Lensch MW, Tischkowitz M, Christianson TA, Reifsteck CA, Speckhart SA, et al: Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood 2003;102:7-16. (Pubitemid 36759629)
30. Tischkowitz MD, Morgan NV, Grimwade D, Eddy C, Ball S, et al: Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 2004;18:420-425. (Pubitemid 38425854)
31. Rischewski JR, Clausen H, Leber V, Niemeyer C, Ritter J, et al: A heterozygous frameshift mutation in the Fanconi anemia C gene in familial T-ALL and secondary malignancy. Klin Padiatr 2000;212:174-176. (Pubitemid 30654812)
32. Barber LM, McGrath HE, Meyer S, Will AM, Birch JM, et al: Constitutional sequence variation in the Fanconi anaemia group C (FANCC) gene in childhood acute myeloid leukaemia. Br J Haematol 2003;121:57-62. (Pubitemid 36461268)
33. Barber LM, Barlow RA, Meyer S, White DJ, Will AM, et al: Inherited FANCD1/BRCA2 exon 7 splice mutations associated with acute myeloid leukaemia in Fanconi anaemia D1 are not found in sporadic childhood leukaemia. Br J Haematol 2005;130:796-797. (Pubitemid 43906656)
34. Meyer S, Barber LM, White DJ, Will AM, Birch JM, et al: Spectrum and significance of variants and mutations in the Fanconi anaemia group G gene in children with sporadic acute myeloid leukaemia. Br J Haematol 2006;133:284-292.
35. Van der Heijden MS, Yeo CJ, Hruban RH, Kern SE: Fanconi anemia gene mutations in youngonset pancreatic cancer. Cancer Res 2003;63:2585-2588. (Pubitemid 36605199)
36. Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, et al: Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005;65:383-386.
37. Rogers CD, Van der Heijden MS, Brune K, Yeo CJ, Hruban RH, et al: The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther 2004;3:167-169. (Pubitemid 41350898)
38. Rogers CD, Couch FJ, Brune K, Martin ST, Philips J, et al: Genetics of the FANCA gene in familial pancreatic cancer. J Med Genet 2004;41:e126.
39. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-2090. (Pubitemid 24325690)
40. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792. (Pubitemid 26004412)
41. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-609. (Pubitemid 34815345)
42. Offit K, Levran O, Mullaney B, Mah K, Nafa K, et al: Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003;95:1548-1551. (Pubitemid 37322099)
43. Wagner JE, Tolar J, Levran O, Scholl T, Deffenbaugh A, et al: Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 2004;103:3226-3229. (Pubitemid 38451703)
44. Wooster R, Weber BL: Breast and ovarian cancer. N Engl J Med 2003;348:2339-2347. (Pubitemid 36638109)
45. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, et al: BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996;13:238-240. (Pubitemid 26000445)
46. Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y: Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 1996;13:245-247. (Pubitemid 26000446)
47. Teng DH, Bogden R, Mitchell J, Baumgard M, Bell R, et al: Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 1996;13:241-244. (Pubitemid 26166161)
48. Weber BH, Brohm M, Stec I, Backe J, Caffier H: A somatic truncating mutation in BRCA2 in a sporadic breast tumor. Am J Hum Genet 1996;59:962-964. (Pubitemid 26328096)
49. Kwiatkowska E, Teresiak M, Breborowicz D, Mackiewicz A: Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer. Int J Cancer 2002;98:943-945. (Pubitemid 34286695)
50. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, De Young B, Buller RE: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-1406. (Pubitemid 35154144)
51. Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, et al: The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 2005;37:931-933. (Pubitemid 43086147)
52. Levitus M, Waisfisz Q, Godthelp BC, De Vries Y, Hussain S, et al: The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005;37:934-935. (Pubitemid 43086148)
53. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, et al: BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 2001;105:149-160. (Pubitemid 32323924)
54. Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, et al: Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer 2004;4:9.
55. Luo L, Lei H, Du Q, Von Wachenfeldt A, Kockum I, et al: No mutations in the BACH1 gene in BRCA1 and BRCA2 negative breast-cancer families linked to 17q22. Int J Cancer 2002;98:638-639. (Pubitemid 34208569)
56. Lewis AG, Flanagan J, Marsh A, Pupo GM, Mann G, et al: Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res 2005;7:R1005-R1016.
57. Vahteristo P, Yliannala K, Tamminen A, Eerola H, Blomqvist C, Nevanlinna H: BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer 2006;6:19.
58. Seal S, Barfoot R, Jayatilake H, Smith P, Renwick A, et al: Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. Cancer Res 2003;63:8596-8599. (Pubitemid 38064032)
59. Thompson E, Dragovic RL, Stephenson SA, Eccles DM, Campbell IG, Dobrovic A: A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer. BMC Cancer 2005;5:43.
60. Barroso E, Milne RL, Fernandez LP, Zamora P, Arias JI, et al: FANCD2 associated with sporadic breast cancer risk. Carcinogenesis 2006;27:1930-1937. (Pubitemid 44307832)
61. Hu N, Li G, Li WJ, Wang C, Goldstein AM, et al: Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma. Clin Cancer Res 2002;8:1121-1126. (Pubitemid 35177365)
62. Sparano A, Quesnelle KM, Kumar MS, Wang Y, Sylvester AJ, et al: Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. Laryngoscope 2006;116:735-741. (Pubitemid 44318029)
63. De Winter JP, Rooimans MA, Van der Weel L, Van Berkel CG, Alon N, et al: The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet 2000;24:15-16. (Pubitemid 30041412)
64. Leveille F, Blom E, Medhurst AL, Bier P, Laghmani El H, et al: The Fanconi anemia gene product FANCF is a flexible adaptor protein. J Biol Chem 2004;279:39421-39430. (Pubitemid 39258207)
65. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, et al: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-574. (Pubitemid 36597103)
66. Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, et al: Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA 2006;103:8822-8827. (Pubitemid 43878103)
67. De Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B, Baylin SB: The short arm of chromosome 11 is a 'hot spot' for hypermethylation in human neoplasia. Proc Natl Acad Sci USA 1988;85:5693-5697.
68. Hoffmann MJ, Florl AR, Seifert HH, Schulz WA: Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 2005;114:406-413. (Pubitemid 40279961)
69. Tischkowitz M, Dokal I: Fanconi anaemia and leukaemia - clinical and molecular aspects. Br J Haematol 2004;126:176-191. (Pubitemid 38961936)
70. Van der Heijden MS, Brody JR, Elghalbzouri-Maghrani E, Zdzienicka MZ, Kern SE: Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers. BMC Genet 2006;7:3.
71. Tischkowitz M, Ameziane N, Waisfisz Q, De Winter JP, Harris R, et al: Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol 2003;123:469-471. (Pubitemid 37363488)
72. Van der Heijden MS, Brody JR, Kern SE: Functional screen of the Fanconi anemia pathway in cancer cells by Fancd2 immunoblot. Cancer Biol Ther 2004;3:534-537. (Pubitemid 41351123)
73. Meyer S, White DJ, Will AM, Eden T, Sim A, et al: No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia. Br J Haematol 2006;134:61-63. (Pubitemid 43830029)
74. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004;23:1000-1004. (Pubitemid 38250946)
75. Olopade OI, Wei M: FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003;3:417-420. (Pubitemid 38340287)
76. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, et al: Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 2004;64:2994-2997. (Pubitemid 38581394)
77. Snyder ER, Ricker JL, Chen Z, Waes CV: Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines. Cancer Lett 2006;245:75-80.
78. Dhillon VS, Shahid M, Husain SA: CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer 2004;3:33.
79. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, et al: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005;65:8961-8967. (Pubitemid 41377387)
80. Wang Z, Li M, Lu S, Zhang Y, Wang H: Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi Anemia-BRCA pathway. Cancer Biol Ther 2006;5:256-260.
81. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, et al: Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer 2004;3:16.
82. Guardiola P, Socié G, Li X, Ribaus P, Devergie A, et al: Acute graft-versus-host disease in patients with Fanconi anemia or aquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood 2004;103:73-77. (Pubitemid 38029920)
83. Seal S, Thompson D, Renwick D, Elliott A, Kelly P, et al: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38:1239-1241. (Pubitemid 44646283)
84. Rahman N, Seil S, Thompson D, Kelly P, Renwick A, et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007;39:165-167. (Pubitemid 46184346)
85. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, et al: A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007;446:316-319. (Pubitemid 46426155)
86. Neveling K, Kalb R, Florl AR, Herterich S, Friedl R, et al: Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res 2007, in press.
87. Van der Groep P, Hoelzel M, Buerger H, Joenje H, De Winter JP, et al: Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2007; Epub ahead of print.